ASPIRE2025 is a partnership between major New Zealand research groups carrying out research to help achieve the Government's goal of a tobacco-free Aotearoa by 2025. ASPIRE2025 brings together leading tobacco-free researchers and health service groups in New Zealand and strengthens existing collaborations. ASPIRE2025 was awarded the status of a University of Otago Research Theme in November 2011.
The Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme has an aim to build capacity and academic rigour in New Zealand in the estimation of disease burden, cost-effectiveness and equity impacts of proposed interventions, and undertake a range of such assessments. It is a Health Research Council (HRC) funded programme, from 2010 to 2015. Major collaborative partners include the University of Queensland and the Ministry of Health.
The Cancer and Chronic Conditions (C3) research group is a collaborative group of researchers working at the interface between public health, health services research, and clinical medicine. Our work includes a range of projects aimed at reducing the impact of cancer and chronic conditions on population health and health inequalities through policy and health system change.
Translational cancer research bridges the gap between laboratory-based science and treatment in the clinic. We now have sufficient knowledge in the fields of cancer biology, molecular biology, and immunology to make a significant impact on the treatment and management of cancer.
We're bringing about rapid improvements in cancer outcomes by addressing defined clinical problems. Our research is accelerating the development and testing of new drugs and diagnostic tools that directly assist clinicians and their patients.
Our research programmes include:
- Personalised medicine
- Inherited and environmental cancer risk
- Childhood cancers
- Diagnostic tools
- Cancer and our immune system
- Drug development
The Health Inequalities Research Programme is a longstanding programme of research hosted by the Department of Public Health, University of Otago, Wellington. HIRP encompasses a series of research projects including the New Zealand Census Mortality and CancerTrends Study (NZCMS/CT), the Healthier Lives National Science Challenge, and the Virtual Health Information Network (VHIN). The aim of HIRP is to capitalise on New Zealand’s Integrated Data Infrastructure (IDI) to provide information to influence and support policies and programmes that will reduce inequalities in health.
The Unit regularly examines trends in cancer incidence, mortality, and survival in New Zealand as well as conducting research into the causes, detection, and prevention of cancer. Collaborative studies are being, or have been, conducted of cancer of the prostate, breast, colon, rectum, cervix, skin (melanoma and non-melanoma skin cancer), stomach, ovary, mouth and oral cavity, lung, head and neck, non-Hodgkin lymphoma and chronic lymphocytic leukaemia in New Zealand. In addition, with biomedical scientists, studies linking specific cancer risk factors with biological mechanisms of cancer development of are being undertaken.
The Unit also specialises in the design, evaluation and monitoring of national cancer screening programmes and the calculation of an individual's risk of specific cancers. The individual risk calculator for melanoma has been accepted internationally. The Unit has numerous collaborations with national and international institutions and also represents New Zealand in the International Cancer Screening Network of the National Cancer Institute (USA) and the International Lung Cancer Consortium of the International Agency for Research on Cancer (WHO).
We are interested in the pathology of human tumours and in identifying the genetic changes that give rise to cancer. Our research focuses on the molecular regulation of tumour growth, metastasis and response to therapy.
The Mackenzie Cancer Research Group hosts the Cancer Society Tissue Bank.
We provide expertise and sequencing resources to New Zealand researchers and industry including:
- Project design and advice
- Illumina HiSeq sequencing
- Illumina MiSeq sequencing
- Nanostring nCounter Analysis System
The Otago Genomics Facility is an Illumina Propel-certified service provider for Illumina HiSeq 2500 and MiSeq sequencing platforms, and is also a Nanostring nCounter Analysis System core facility.
Current research activities within the Department focus on the causes and behaviour of various cancers with a specific emphasis on prostrate, kidney, breast, cervix, and bladder malignancy. Urogenital pathology and dental research are also areas of research interest.
The Division of Health Sciences benefits from its high calibre of staff and their wide range of skills and research expertise.
Our Staff Expertise Database provides details on University of Otago, Health Sciences staff. Each staff profile provides information on qualifications, current academic position, contact details, and a summary of research and publications.
You can search our database by keyword (eg cancer) or by name.
The Social and Behavioural Research Unit was established in 1990 with core funding from the Cancer Society of New Zealand and the support of the University of Otago. Presently it has research programmes in priority areas of tobacco control, ultraviolet radiation exposure, physical activity and nutrition, psycho-social-spiritual factors, alcohol, and Hauora Māori.
Te Rōpū Rangahau Hauora a Eru Pōmare strives to create a Kaupapa Māori space committed to improving Māori health outcomes and eliminating inequalities through quality science and ongoing theoretical development. It takes a rights-based approach consistent with the Treaty of Waitangi, and is engaged with community through a spectrum of influence from community development, policy advocacy, research dissemination and Māori health research workforce development.